The CEO of Airna said the company is ﬁrst focusing on developing a drug for alpha1 antitrypsin deﬁciency Permission granted by AIRNA  Airna a biotechnology startup focused on RNA editing to make more precise medicines emerged from stealth Tuesday with 30 million in hand